ArticleVaccine2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Open access · hybridAbstract read
In one paragraph
Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Aluminum adjuvants differentially induce IL-1β release in vitro yet share NLRP3 inflammasome-independent adjuvant effects in vivo.Scientific reports · 2026Article
- Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection.Vaccines · 2025Article
- Mucosal Vaccination Against SARS-CoV-2 Using Human ProbioticVaccines · 2025Article
- Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate.Scientific reports · 2025Article
- Protective immunity induced by a novel P1 adhesin C-terminal anchored mRNA vaccine againstMicrobiology spectrum · 2025Article
- Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.Current drug targets · 2025Review
- Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2.Frontiers in immunology · 2025Article
- Backstage Heroes-Yeast in COVID-19 Research.International journal of molecular sciences · 2024Review
- Article
- Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.Viruses · 2024Article
- Vaccine Science Diplomacy and "The Phenomenon of Man".The Linacre quarterly · 2024Article
- A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.NPJ vaccines · 2024Article
- A Journey in Science: Molecular vaccines for global child health in troubled times of anti-science.Molecular medicine (Cambridge, Mass.) · 2024Article
- Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.Frontiers in immunology · 2024Article
- Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine.Frontiers in drug delivery · 2024Article
- Th2 and Th17-associated immunopathology following SARS-CoV-2 breakthrough infection in Spike-vaccinated ACE2-humanized mice.Journal of medical virology · 2024Article
- A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2023Article
- Th2 and Th17-Associated Immunopathology Following SARS-CoV-2 Breakthrough Infection in Spike-Vaccinated ACE2-humanized Mice.bioRxiv : the preprint server for biology · 2023Article
- A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.Vaccines · 2023Article
- Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
- Update of
Authors and funding
22 authors at 4 institutions in 2 countries.
Jeroen PolletTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Ulrich StrychTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Wen-Hsiang ChenTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Leroy VersteegTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Brian KeeganTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Bin ZhanTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Junfei WeiTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Zhuyun LiuTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Jungsoon LeeTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Rahki KunduTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Rakesh AdhikariTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Cristina PovedaTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Maria Jose VillarTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Syamala Rani ThimmirajuTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Brianna LopezDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Portia M GillespieTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Shannon RoncaDepartment of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Jason T KimataDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Martin ReersBiological E, Limited, Hyderabad, India.
Vikram ParadkarBiological E, Limited, Hyderabad, India.
Peter J HotezTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA; James A. Baker III Institute for Public Policy, Rice University, Houston, TX, USA.
Maria Elena BottazziTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA. Electronic address: bottazzi@bcm.edu.
Texas Children's Hospital · USBaylor College of Medicine · USBaylor University · USBiological E (India) · IN
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the Corbevax
Indexed as
COVID-19SARS-CoV-2Alum CompoundsAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyCOVID-19 VaccinesHumansImmunization, PassiveMiceRecombinant ProteinsSpike Glycoprotein, CoronavirusAlum Compoundsaluminum sulfateAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesRecombinant ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CorbevaxCOVID-19Subunit vaccineTLR9 adjuvantVirus neutralization
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.